Modulators of cystic fibrosis transmembrane conductance regulator
AssigneeVertex Pharmaceuticals Incorporated
InventorsHayley Binch, Lev T. D. Fanning, Dennis Hurley, Urvi Sheth, Alina Silina, Xiaoqing Yang, Martyn Botfield, Peter D. J. Grootenhuis, Fredrick Van Goor, Mehdi Michel Djamel Numa
Life of this patent
Estimating the term…
Abstract
The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.
Claims11
A method of treating or lessening the severity of a disease in a patient, wherein the disease is cystic fibrosis, COPD, smoked induced COPD, hereditary emphysema, pancreatitis, pancreatic insufficiency or dry-eye disease, said method comprising the step of administering to said patient an effective amount of a compound of Formula (I):
- or pharmaceutically acceptable salts thereof, wherein
- ring A is selected from
- R1 is —CF3, —CN, or —C≡CCH2N(CH3)2;
- R2 is hydrogen, —CH3, —CF3, —OH, or —CH2OH;
- and
- R3 is hydrogen, —CH3, —OCH3, or —CN;
- provided that both R2 and R3 are not simultaneously hydrogen.
A method of modulating CFTR activity in a patient comprising the step of contacting said CFTR with a compound of Formula (I):
- or pharmaceutically acceptable salts thereof, wherein
- ring A is selected from
- R1 is —CF3, —CN, or —C≡CCH2N(CH3)2;
- R2 is hydrogen, —CH3, —CF3, —OH, or —CH2OH;
- and
- R3 is hydrogen, —CH3, —OCH3, or —CN;
- provided that both R2 and R3 are not simultaneously hydrogen.
Dependencies are inferred from the claim text.